CARsgen Therapeutics Holdings Limited (HK:2171), a Chinese developer of innovative CAR T-cell therapies, announced on Monday that the long-term analysis results of satricabtagene autoleucel (satri-cel, CT041) (an autologous CAR T-cell product candidate against Claudin18.2), as sequential therapy after first-line (1L) treatment in patients with advanced gastric/gastroesophageal junction adenocarcinoma (G/GEJA), have been presented at the 2026 ASCO Annual Meeting.

The poster was titled 'Long-term Follow-up of Satricabtagene autoleucel (satri-cel) as Sequential Therapy After First-Line Treatment for Advanced Gastric Cancer -- a subgroup analysis'.

The investigator-initiated trial, CT041-CG4006, is an open-label, multi-cohort, phase 1 study designed to evaluate the safety and efficacy of satri-cel in patients with Claudin18.2-positive advanced gastrointestinal cancers. Results from all cohorts were published in Nature Medicine and presented at the ASCO Annual Meeting in 2024. The 2026 ASCO Annual Meeting features the long-term follow-up results of Cohort 3 from this study, with a follow-up duration exceeding 4.5 years.

As of 18 October 2025, the median follow-up of the 5 patients from initial 1L therapy was 54.6 months. Among the 4 patients with target lesions, the confirmed objective response rate (ORR) was 100%, and the median duration of response (DOR) was not reached. The one patient without target lesions maintained stable for 20.9 months. Among the 5 patients, the median progression-free survival (PFS) since 1L therapy was 20.9 months. Among these, 2 patients, with significant clinical benefit, underwent surgical resection after satri-cel therapy. As of the data cutoff date, both patients remained alive, with follow-up durations of 58.1 months and 51.1 months.

According to CARsgen, with a long-term follow-up exceeding 4.5 years, satri-cel as 1L sequential treatment continues to demonstrate durable survival benefit with a manageable safety profile in patients with advanced G/GEJ cancer, supporting its highly promising potential and clinical value in earlier lines of therapy.